Lupin Ltd's Q4FY25 Quarter Results
- 15 May 2025
Result Summary
- Lupin Ltd reported a 14.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 11.7%.
- Its expenses for the quarter were down by 5.4% QoQ and up 6.7% YoY.
- The net profit decreased 57.1% QoQ and increased 51.9% YoY.
- The earnings per share (EPS) of Lupin Ltd stood at 7.9 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 4990.04 | 5821.42 | 4467.35 | -14.3% | 11.7% |
Total Expenses | 4492.33 | 4750.15 | 4208.85 | -5.4% | 6.7% |
Profit Before Tax | 497.71 | 1071.27 | 258.50 | -53.5% | 92.5% |
Tax | 129.49 | 212.41 | 16.11 | -39.0% | 703.8% |
Profit After Tax | 368.22 | 858.86 | 242.39 | -57.1% | 51.9% |
Earnings Per Share | 7.90 | 18.70 | 5.20 | -57.8% | 51.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Lupin Ltd is a prominent entity in the pharmaceutical industry, focusing on the development and manufacturing of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients globally. It holds a significant position in the market with a comprehensive portfolio of products that cater to various therapeutic areas including cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. As of the latest data available, Lupin Ltd continues to expand its global reach and enhance its product offerings through strategic acquisitions and partnerships, although specific recent developments beyond October 2023 are not available.
Revenue
In Q4FY25, Lupin Ltd reported a total income of ₹4990.04 crores, compared to ₹5821.42 crores in Q3FY25, indicating a quarter-over-quarter (QoQ) decline of 14.3%. However, when compared to the same quarter in the previous year, Q4FY24, where the total income was ₹4467.35 crores, the company experienced an 11.7% year-over-year (YoY) increase. This fluctuation signifies a dynamic revenue environment over the respective quarters. The reported figures suggest variances in the revenue stream which could be attributed to multiple factors such as market demand, pricing strategies, and competitive positioning within the pharmaceutical sector.
Profitability
Lupin Ltd's profitability metrics for Q4FY25 show a Profit Before Tax (PBT) of ₹497.71 crores, which is down from ₹1071.27 crores in Q3FY25, reflecting a QoQ decrease of 53.5%. However, compared to Q4FY24, with a PBT of ₹258.50 crores, there is a significant YoY growth of 92.5%. The tax expenses for Q4FY25 were ₹129.49 crores, representing a decrease from ₹212.41 crores in the previous quarter but a substantial increase from ₹16.11 crores in Q4FY24. Consequently, the Profit After Tax (PAT) for Q4FY25 was ₹368.22 crores, which shows a reduction from ₹858.86 crores in Q3FY25, yet an increase from ₹242.39 crores in Q4FY24. The Earnings Per Share (EPS) followed a similar trend, being ₹7.90 in Q4FY25 compared to ₹18.70 in Q3FY25 and ₹5.20 in Q4FY24, highlighting a substantial YoY growth of 51.9%.
Operating Metrics
The total expenses for Lupin Ltd in Q4FY25 were ₹4492.33 crores, which decreased by 5.4% compared to ₹4750.15 crores in Q3FY25. This represents a YoY increase of 6.7% from ₹4208.85 crores in Q4FY24. The reduction in quarterly expenses, alongside the income trends, reflects on the operational adjustments within the quarter. The operating environment of the company is characterized by its ability to manage costs relative to income shifts, which is critical in maintaining financial stability. The analysis of these metrics is crucial in understanding the company's operational effectiveness during the reported periods.
